Stocks Comparison
Halozyme Therapeutics vs Neurocrine Biosciences: revenue, profit, margins and growth compared
Halozyme Therapeutics brought in $1.4B of revenue in fiscal 2025, Neurocrine Biosciences $2.9B in fiscal 2025. Revenue changed by +37.6% at Halozyme Therapeutics and +21.4% at Neurocrine Biosciences on the year before, so Halozyme Therapeutics grew faster. Halozyme Therapeutics kept 22.7% of its revenue as net profit, Neurocrine Biosciences 16.7%. Free cash flow was $644.6M at Halozyme Therapeutics and $748.7M at Neurocrine Biosciences.
Side by side, latest fiscal year
| HALO | NBIX | |
|---|---|---|
| Fiscal year ended | FY2025 (December 31, 2025) | FY2025 (December 31, 2025) |
| Revenue | $1.4B | $2.9B |
| Revenue growth | +37.6% | +21.4% |
| Net income | $316.9M | $478.6M |
| Net margin | 22.7% | 16.7% |
| Free cash flow | $644.6M | $748.7M |
| Free cash flow margin | 46.2% | 26.2% |
| Earnings per share (diluted) | $2.56 | $4.67 |
| Cash | $133.8M | $713M |
| Debt | $2.1B | n/a |
| Price to earnings | 44.5 | 29.6 |
| Market value | $12.9B | $14.1B |
| Dividend yield | n/a | n/a |
| Rank by revenue in sector | #129 of 523 · Health care | #88 of 523 · Health care |
Over the years
Questions about Halozyme Therapeutics and Neurocrine Biosciences
Which is bigger by revenue, Halozyme Therapeutics or Neurocrine Biosciences?
Neurocrine Biosciences is bigger by revenue: $2.9B in fiscal 2025, against $1.4B for Halozyme Therapeutics in fiscal 2025.
Which keeps more of its revenue as profit, Halozyme Therapeutics or Neurocrine Biosciences?
Halozyme Therapeutics had a net margin of 22.7% in fiscal 2025; Neurocrine Biosciences had 16.7% in fiscal 2025.
Which grew revenue faster, Halozyme Therapeutics or Neurocrine Biosciences?
In their latest fiscal years revenue changed by +37.6% at Halozyme Therapeutics and +21.4% at Neurocrine Biosciences.
Where do these numbers come from?
From the annual reports each company files with the SEC (10-K, or 20-F and 40-F for foreign companies), read from their XBRL data. Margins and growth are simple arithmetic on those figures. Nothing here is a recommendation.